Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

GlaxoSmithKline Adopts Multi-Faceted Strategy for China

publication date: Mar 5, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
GlaxoSmithKline is willing to explore all paths to increase its China presence. CEO Andrew Witty said the company is looking at a range of strategies in China, including acquisitions, more SFDA drug approvals, building its R&D effort, and adding personnel to its already large 4,000 member sales force. Even though China’s government is reducing prices on drugs, China’s market – already big and growing quickly – is too attractive a target for GSK to ignore. More details....

Stock Symbol: (NYSE: GSK)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...